BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

...therapies approved for vascular cognitive impairment. Multiple clinical trials have evaluated AD drugs, such as cholinesterase...
BioCentury | Jan 19, 2018
Strategy

After amyloid

...both β amyloid and tau were counted in both categories. New formulations ( e.g. , cholinesterase...
BioCentury | Sep 5, 2016
Company News

Qaam Pharmaceuticals, Axovant Sciences deal

...Qaam granted Axovant an exclusive license to IP that covers the combination of cholinesterase inhibitors with...
...peripheral muscarinic receptor antagonists. Axovant said the combination could mitigate the peripheral side effects of cholinesterase...
BioCentury | Aug 3, 2015
Clinical News

Ladostigil: Interim Phase IIb data

...Pharmaceuticals Ltd. , Yavneh, Israel Product: Ladostigil Business: Neurology Molecular target: Monoamine oxidase (MAO) Description: Cholinesterase...
BioCentury | Jul 27, 2015
Clinical News

Amyvid florbetapir: Clinical trial data

...status, health outcomes/resource utilization, mood, function and quality of life (QOL). In the immediate-feedback group, cholinesterase...
...in amyloid-positive patients and decreased in amyloid-negative patients (67% vs. 27%). In the delayed-feedback group, cholinesterase...
BioCentury | Jul 24, 2015
Clinical News

Lilly study links Amyvid to changes in treatment

...group vs. 56% in the delayed feedback group. In the immediate feedback group, treatment with cholinesterase...
...inhibitors increased in amyloid-positive patients and decreased in amyloid-negative patients; 67% of amyloid-positive patients received cholinesterase...
...amyloid-negative patients. However, for patients in the delayed feedback group, 56% of amyloid-positive patients received cholinesterase...
BioCentury | Feb 16, 2015
Clinical News

Masican masitinib: Phase III ongoing

...24-week treatment period. The trial is evaluating 3 and 4.5 mg/kg masitinib in combination with cholinesterase...
BioCentury | Jan 19, 2015
Clinical News

SYN120: Phase IIa started

...for 16 weeks in about 80 patients already treated with a stable dose of a cholinesterase...
BioCentury | Jul 14, 2014
Clinical News

Ladostigil: Phase IIb ongoing

...2010). Avraham Pharmaceuticals Ltd ., Yavneh, Israel Product: Ladostigil Business: Neurology Molecular target: NA Description: Cholinesterase...
BioCentury | Apr 14, 2014
Analyst Picks & Changes

Analyst picks & changes

...year to reverse the effects of non-depolarizing neuromuscular blocking agents after surgery. Flamel obtained the cholinesterase...
Items per page:
1 - 10 of 55